Yakult expands oncology pipeline with Proacta deal
This article was originally published in Scrip
Executive Summary
Japan's Yakult Honsha has acquired exclusive development and commercialisation rights in Japan to Proacta's irreversible multi-kinase inhibitor (MKI) for cancer PR509.